TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06403215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum group
Description: Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fennel tea group
Description: Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum+Fennel tea group
Description: Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention
Study: NCT03222037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Acuvue Oasys 1-Day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Acuvue Oasys 1-Day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Trial Frame with best spherocylindrical refraction (SCR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Trial Frame with best spherocylindrical refraction (SCR)
Study: NCT04164758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
Study: NCT03869424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Placebo labelled as antidepessant
Description: Participants receive an active nasal spray that is in fact a placebo.
Study: NCT05475431

Intervention type: DRUG
Intervention: The sequential therapy
Description: Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days

Intervention type: DRUG
Intervention: The sequential therapy
Description: Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days

Intervention type: DRUG
Intervention: The triple therapy
Description: Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.

Intervention type: DRUG
Intervention: The triple therapy
Description: Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.

Intervention type: DRUG
Intervention: The hybrid therapy
Description: Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .

Intervention type: DRUG
Intervention: The hybrid therapy
Description: Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .

Intervention type: DRUG
Intervention: The concomitant therapy
Description: Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days

Intervention type: DRUG
Intervention: The concomitant therapy
Description: Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days

Intervention type: DRUG
Intervention: Bismuth-based quadruple therapy
Description: Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
Study: NCT03788044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education + Medication adherence monitoring + Feedback when low adherence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education + Medication adherence monitoring + Feedback when low adherence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education + Medication adherence monitoring + Feedback when low adherence
Study: NCT03253627

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
Study: NCT05475431

Intervention type: DRUG
Intervention: Bismuth-based quadruple therapy
Description: Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
Study: NCT04432207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 1
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 1
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 1
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
Study: NCT03253627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
Study: NCT03079778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization
Description: Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Description: Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE plus RT
Description: radiobiologically guided radiation
Study: NCT01303328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C1
Description: Local application of the experimental gel or placebo gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1
Description: Local application of the experimental gel or placebo gel.
Study: NCT04595331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection
Description: Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
Study: NCT02919371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
Study: NCT02563977

Intervention type: DEVICE
Intervention: 2 year postop CT scan of the abdomen
Description: CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
Study: NCT01180374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Active Cannabidiol 5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint.
Study: NCT02786329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA+lidocaine
Description: Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane+lidocaine
Description: Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TIVA+placebo
Description: Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane+placebo
Description: Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
Study: NCT01840072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment
Description: Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
Study: NCT02487329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
Study: NCT00195273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: 15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
Study: NCT02487329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser + calcium hydroxide
Description: After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Description: TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser + TheraCal LC
Description: After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
Study: NCT02260232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Study: NCT01180374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint.
Study: NCT00195273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
Study: NCT02199912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of adipose and muscular tissue
Study: NCT00195273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab
Description: IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
Study: NCT04432207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 1
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
Study: NCT02199912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorimetry
Study: NCT02910362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon phacoemulsification equipment
Description: cataract surgery with Alcon phacoemulsification equipment.
Study: NCT02199912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impedance measure
Description: Evaluation of physical composition (non-invasive method)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of nutritional status
Description: Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of physical performance
Description: This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of muscular strength
Description: Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of emotional status
Description: The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of functional status
Description: The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
Study: NCT02910362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO phacoemulsification equipment
Description: cataract surgery with AMO phacoemulsification equipment.
Study: NCT02116231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with cisplatin
Description: Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy is a technique of radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy is a technique of radiotherapy.
Study: NCT05059171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OneSahpe single file
Description: The rotary motion of OneShape single file

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold single file
Description: reciprocation motions of WaveOne Gold single file
Study: NCT03025841

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline
Study: NCT00962338

Intervention type: BEHAVIORAL
Intervention: Information
Description: Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
Study: NCT01871922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine
Study: NCT04011241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study: NCT03653819

Intervention type: OTHER
Group type: OTHER
Intervention: First exercise session + compression
Description: The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.

Intervention type: OTHER
Group type: OTHER
Intervention: First exercise session - compression
Description: The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
Study: NCT04432207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 2
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
Study: NCT01256047

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
Study: NCT05781685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Syrup
Description: Oil-based sublingual product.
Study: NCT05781685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Syrup
Description: Oil-based sublingual product.